EuBiologics Co., Ltd. (206650.KQ)
KRW 12240.0
(3.9%)
KRW 12240.0
(3.9%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -4.39 Billion KRW | 310.04% |
| 2022 | 5.37 Billion KRW | 718.09% |
| 2021 | -23.29 Billion KRW | -4944.76% |
| 2020 | -52.5 Billion KRW | -100.1% |
| 2019 | 2.66 Billion KRW | 75.76% |
| 2018 | 3.3 Billion KRW | 331.03% |
| 2017 | -2.73 Billion KRW | 40.96% |
| 2016 | -4.54 Billion KRW | -271.54% |
| 2015 | -406.82 Million KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 4.66 Billion KRW | 88.59% |
| 2024 Q2 | 650.47 Million KRW | 195.64% |
| 2023 Q3 | -949.32 Million KRW | -121.94% |
| 2023 Q2 | 4.32 Billion KRW | 157.48% |
| 2023 FY | - KRW | 310.04% |
| 2023 Q1 | 1.68 Billion KRW | 274.18% |
| 2023 Q4 | 11.8 Billion KRW | 1343.93% |
| 2022 Q1 | 1.5 Billion KRW | 312.86% |
| 2022 FY | - KRW | 718.09% |
| 2022 Q3 | 1.13 Billion KRW | -53.48% |
| 2022 Q2 | 2.43 Billion KRW | 62.24% |
| 2022 Q4 | -964.83 Million KRW | -185.01% |
| 2021 Q3 | 3.14 Billion KRW | 463.18% |
| 2021 Q1 | -2.23 Billion KRW | 0.0% |
| 2021 FY | - KRW | -4944.76% |
| 2021 Q2 | -866.13 Million KRW | 61.31% |
| 2021 Q4 | -706.42 Million KRW | -122.46% |
| 2020 FY | - KRW | -100.1% |
| 2019 FY | - KRW | 75.76% |
| 2018 FY | - KRW | 331.03% |
| 2017 FY | - KRW | 40.96% |
| 2016 FY | - KRW | -271.54% |
| 2015 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 581.09 Million KRW | 855.79% |
| CMG Pharmaceutical Co., Ltd. | 5.59 Billion KRW | 178.502% |
| Celltrion Pharm, Inc. | 54.22 Billion KRW | 108.099% |
| Huons Global Co., Ltd. | 151.92 Billion KRW | 102.891% |
| DongKook Pharmaceutical Co., Ltd. | 88.68 Billion KRW | 104.952% |
| Enzychem Lifesciences Corporation | -5.77 Billion KRW | 23.934% |
| Humedix Co., Ltd. | 54.87 Billion KRW | 108.003% |
| Boditech Med Inc. | 36.48 Billion KRW | 112.036% |
| FutureChem Co.,Ltd | -591.25 Million KRW | -642.795% |
| Huons Co., Ltd. | 74.23 Billion KRW | 105.916% |
| BNC Korea Co., Ltd. | 14.17 Billion KRW | 130.991% |
| AptaBio Therapeutics Inc. | -13 Billion KRW | 66.229% |